Exposure–Response‐Based Product Profile–Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer

The aims of this work were to characterize ipatasertib exposure–response (E‐R) relationships in a phase II study and to quantitatively assess benefit‐risk using a clinical utility index approach to support ipatasertib phase III dose selection in patients with metastatic castration‐resistant prostate...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Rui, Poland, Bill, Wada, Russ, Liu, Qi, Musib, Luna, Maslyar, Daniel, Cho, Eunpi, Yu, Wei, Ma, Han, Jin, Jin Yan, Budha, Nageshwar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482275/
https://www.ncbi.nlm.nih.gov/pubmed/30762302
http://dx.doi.org/10.1002/psp4.12394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482275/
https://www.ncbi.nlm.nih.gov/pubmed/30762302
http://dx.doi.org/10.1002/psp4.12394

Ejemplares similares